Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Eligibility Criteria

Inclusion Criteria:

* GROUP 1 FOCUS GROUPS:

* Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
* GROUP 1 SURVEYS:

* Are 18 years of age or older
* Have histologic evidence of prostate adenocarcinoma
* Are requiring, have required, or will require prostate cancer treatment
* Have an understanding of the protocol and its requirements
* Are willing to fill in a questionnaire and participate in a focused interview
* Are able and willing to sign an informed consent
* GROUP 1 INTERVIEWS:

* Enrollment in the survey phase of the protocol
* GROUP 2:

* Are 18 years of age or older
* Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
* Have histologic evidence of prostate adenocarcinoma
* Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
* Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
* Have an understanding of the protocol and its requirements
* Are able and willing to sign informed consent

Exclusion Criteria:

* GROUP 1 FOCUS GROUPS:

* Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
* GROUP 1 SURVEYS:

* Do not identify as Black men
* Have not been diagnosed with prostate cancer
* GROUP 1 INTERVIEWS:

* Not enrolled in the survey phase of the protocol
* GROUP 2:

* Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
* Have not been diagnosed with histologic evidence of prostate adenocarcinoma
* Are not requiring active standard anti-cancer therapy